JPMorgan Chase Reduces Stake in Tandem Diabetes Care

Institutional investor sells over 200,000 shares of medical device company

Apr. 3, 2026 at 9:05am

Got story updates? Submit your updates here. ›

A high-contrast black and white close-up image of the inner workings of an insulin pump, with gears, circuits, and other mechanical components filling the frame to represent the complex financial and technological infrastructure behind medical device innovation.The sale of over 200,000 Tandem Diabetes shares by JPMorgan Chase highlights the complex financial and technological landscape behind the medical device industry.San Diego Today

JPMorgan Chase & Co. has lowered its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 36.1% during the 3rd quarter, according to a recent SEC filing. The institutional investor sold 203,183 shares of the medical device company's stock, reducing its total holdings to 359,071 shares worth $4.36 million.

Why it matters

This move by a major institutional investor like JPMorgan Chase could signal a shift in market sentiment around Tandem Diabetes Care. As a leading provider of insulin delivery systems, the company's performance is closely watched by analysts and investors in the healthcare technology sector.

The details

According to the filing, JPMorgan Chase & Co. now owns 0.53% of Tandem Diabetes Care's outstanding shares, down from 0.83% previously. The sale comes amid a period of volatility for the stock, which has traded between $9.98 and $29.65 over the past 52 weeks.

  • JPMorgan Chase & Co. sold the shares during the 3rd quarter of the company's fiscal year.

The players

Tandem Diabetes Care, Inc.

A medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes.

JPMorgan Chase & Co.

A multinational investment bank and financial services company that is one of the largest institutional investors in Tandem Diabetes Care.

Got photos? Submit your photos here. ›

The takeaway

This reduction in JPMorgan Chase's stake in Tandem Diabetes Care could signal broader market uncertainty around the company's future prospects, despite its position as a leader in the insulin delivery technology space. Investors will be closely watching to see if other major institutions follow suit or if Tandem can regain investor confidence.